公开(公告)号：US08529251B2

公开(公告)日：2013-09-10

申请号：US12842594

申请日：2010-07-23

Applicant: Hiroki Kumagai ,  Fumihiko Kato ,  Sadahiko Kawasaki

Inventor： Hiroki Kumagai ,  Fumihiko Kato ,  Sadahiko Kawasaki

IPC: F27B7/08 ,  F27B7/36 ,  F27B7/22 ,  F27B7/38

CPC classification number: F27B7/20 ,  F27B7/22 ,  F27B7/26 ,  F27B7/36 ,  F27B7/38

Abstract: A rotary kiln includes: a cylindrical shell that includes a supply-side end portion and a discharge-side end portion at both ends in an axial direction of the shell, and a heat treatment chamber which is defined inside the shell and in which a heat treatment is performed on a process material; a supply-side holder that holds the supply-side end portion; a discharge-side holder that holds the discharge-side end portion; a supply-side rotary shaft that allows rotation of the supply-side holder; and a discharge-side rotary shaft that allows rotation of the discharge-side holder. The shell is rotated about its own axis by rotating at least one of the supply-side rotary shaft and the discharge-side rotary shaft.

Abstract translation: 回转窑包括：圆筒壳体，其包括在壳体的轴向两端的供给侧端部和排出侧端部，以及限定在壳体内部的热处理室， 对处理材料进行处理; 供给侧保持器，其保持供给侧端部; 排出侧保持器，其保持所述排出侧端部; 供给侧旋转轴，其允许供给侧保持架的旋转; 以及允许排出侧保持架旋转的排出侧旋转轴。 通过旋转供给侧旋转轴和排出侧旋转轴中的至少一个，壳体围绕其自身的轴线旋转。

公开(公告)号：US08500444B2

公开(公告)日：2013-08-06

申请号：US12842582

申请日：2010-07-23

Applicant: Hiroki Kumagai ,  Fumihiko Kato ,  Sadahiko Kawasaki

Inventor： Hiroki Kumagai ,  Fumihiko Kato ,  Sadahiko Kawasaki

IPC: F27B7/36

CPC classification number: F27B7/3205 ,  F27B7/26 ,  F27B7/34 ,  F27B7/38 ,  F27D3/08 ,  F27D9/00 ,  H01M4/5825 ,  H01M4/587

Abstract: A rotary kiln includes a cylindrical shell that rotates about its own axis and that has a heat treatment chamber provided radially inward of the shell. In the rotary kiln, a heat treatment is performed on a process material in the heat treatment chamber to manufacture a battery material. The shell is made of a carbon material. Since the shell is made of a carbon material, the rotary kiln can suppress contamination of metal scale, which adversely affects the battery material, into the battery material.

Abstract translation: 旋转窑包括围绕其自身轴线旋转的圆柱形壳体，并且具有设置在壳体的径向内侧的热处理室。 在回转窑中，对热处理室中的处理材料进行热处理以制造电池材料。 壳由碳材料制成。 由于外壳由碳材料制成，所以回转窑可以抑制电池材料对电池材料的不良影响的金属垢的污染。

公开(公告)号：US20110191807A1

公开(公告)日：2011-08-04

申请号：US12892763

申请日：2010-09-28

Applicant: Hiroki Kumagai

Inventor： Hiroki Kumagai

IPC: H04N5/445

CPC classification number: H04N5/445 ,  H04N21/42661 ,  H04N21/433 ,  H04N21/4622 ,  H04N21/47214 ,  H04N21/4782 ,  H04N21/4821 ,  H04N21/8133 ,  H04N21/84

Abstract: In one embodiment, there is provided an electronic device. The device includes: a program-related information receiver configured to receive program-related information provided by broadcast waves; a page data receiver configured to receive data of a Web page at a given time based on text data included in the program-related information; and a storage configured to store the data of the Web page in a storage medium.

Abstract translation: 在一个实施例中，提供了一种电子设备。 该装置包括：被配置为接收由广播波提供的节目相关信息的节目相关信息接收器; 页面数据接收器，被配置为基于包括在节目相关信息中的文本数据在给定时间接收网页的数据; 以及被配置为将所述网页的数据存储在存储介质中的存储器。

公开(公告)号：US06653345B2

公开(公告)日：2003-11-25

申请号：US10139658

申请日：2002-05-06

Applicant: Hajimu Kurumatani ,  Rie Sasaki ,  Hiroki Kumagai

Inventor： Hajimu Kurumatani ,  Rie Sasaki ,  Hiroki Kumagai

IPC: A61K31343

CPC classification number: C07D307/93 ,  A61K31/5585

Abstract: A method of inhibiting mammalian C—C chemokine production by using a mammalian C—C chemokine synthesis inhibitor containing a prostaglandin I derivative as an active component to treat a variety of circulatory diseases, inflammation, allergic diseases, and renal diseases.

Abstract translation: 通过使用含有前列腺素I衍生物作为活性成分的哺乳动物C-C趋化因子合成抑制剂来抑制哺乳动物C-C趋化因子产生的方法，用于治疗各种循环系统疾病，炎症，过敏性疾病和肾脏疾病。

公开(公告)号：US5703687A

公开(公告)日：1997-12-30

申请号：US703695

申请日：1996-08-27

Applicant: Hiroki Kumagai ,  Fumio Fukazawa

Inventor： Hiroki Kumagai ,  Fumio Fukazawa

IPC: A63B45/00 ,  A63B47/00 ,  G01B11/24 ,  G01B11/30 ,  G01N21/88

CPC classification number: G01N21/8803

Abstract: An undesirable protrusion on a golf ball is automatically detected by means of an optical system. Light (5) is illuminated to a selected position (3) on the spherical surface of a golf ball (1a) in a tangential direction. The ball (1a) is rotated in line with the light illuminating direction. A line sensor camera (6) is operated to take a line image of the spherical surface in the vicinity of the selected position and along a line perpendicular to the light illuminating direction. A two-dimensional image is constructed from image data of the camera. An abnormal brightness change which appears in the two-dimensional image as a result of an undesirable protrusion (9a, 9b) on the spherical surface shutting out the light (5) is detected, thereby detecting the presence of the undesirable protrusion.

Abstract translation: 通过光学系统自动检测高尔夫球上不期望的突起。 光（5）沿切线方向照射到高尔夫球（1a）的球形表面上的选定位置（3）。 球（1a）与光照射方向一致地旋转。 线传感器摄像机（6）被操作以沿着与所述光照射方向垂直的线在所选择的位置附近拍摄球面的直线图像。 从相机的图像数据构建二维图像。 检测由于在关闭光（5）的球面上的不期望的突起（9a，9b）而在二维图像中出现的异常亮度变化，从而检测不期望的突起的存在。

公开(公告)号：US09492422B2

公开(公告)日：2016-11-15

申请号：US13509483

申请日：2010-11-12

Applicant: Takehiro Takahashi ,  Hiroki Kumagai ,  Takashi Kadowaki ,  Naoto Kubota ,  Tetsuya Kubota

Inventor： Takehiro Takahashi ,  Hiroki Kumagai ,  Takashi Kadowaki ,  Naoto Kubota ,  Tetsuya Kubota

IPC: A61K31/5585 ,  A61P31/10 ,  A61K31/343 ,  A61K31/4439 ,  A61K31/5575

CPC classification number: A61K31/343 ,  A61K31/4439 ,  A61K31/5575 ,  A61K2300/00

Abstract: A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.

Abstract translation: 用于糖尿病的治疗或预防剂包括作为PPAR-γ激动剂的噻唑烷衍生物作为有效成分，其表现出PPAR-γ激动剂的副作用降低。 用于糖尿病的治疗或预防剂包括特定的IP激动剂如贝前列素钠（BPS）和吡咯烷衍生物如吡格列酮或其药学上可接受的盐。 由于治疗或预防剂表现出足够有效的降血糖作用，而不伴随PPAR-γ激动剂特征的副作用，因此该药剂可用作糖尿病的高度安全有效的治疗或预防剂。

公开(公告)号：US20070046495A1

公开(公告)日：2007-03-01

申请号：US11494461

申请日：2006-07-28

Applicant: Hiroki Kumagai

Inventor： Hiroki Kumagai

IPC: G08C19/00

CPC classification number: G08C17/00

Abstract: According to one embodiment, an electronic apparatus which is installed in an environment in which the apparatus receives a remote control signal from the same remote controller in common with other electronic apparatuses, including a receiving unit configured to receive the remote control signal, a determination unit configured to determine one electronic apparatus to receive the remote control signal among at least one or more electronic apparatuses including the electronic apparatus able to receive the remote control signal, and a setting unit configured to operate to accept the remote control signal received by the receiving unit when a determination result resulting from the determination unit shows the electronic apparatus as the one to receive the remote control, and to operate so as to disregard the remote control signal received by the receiving unit when the result shows electronic apparatuses other than the electronic apparatus.

Abstract translation: 根据一个实施例，一种电子设备，其安装在该设备从与该其他电子设备共同的遥控器接收远程控制信号的环境中，该电子设备包括被配置为接收遥控信号的接收单元，确定单元 被配置为确定在包括能够接收遥控信号的电子设备的至少一个或多个电子设备中接收遥控信号的一个电子设备;以及设置单元，被配置为操作以接收由接收单元接收的遥控信号 当确定单元产生的确定结果示出了作为接收遥控器的电子设备时，并且当结果示出除电子设备之外的电子设备时，操作以忽略由接收单元接收的遥控信号。

公开(公告)号：US06642228B1

公开(公告)日：2003-11-04

申请号：US09763684

申请日：2001-04-13

Applicant: Ryoji Hayashi ,  Eiji Ohmori ,  Masafumi Isogaya ,  Mitsuhiro Moriwaki ,  Hiroki Kumagai

Inventor： Ryoji Hayashi ,  Eiji Ohmori ,  Masafumi Isogaya ,  Mitsuhiro Moriwaki ,  Hiroki Kumagai

IPC: C07D40104

CPC classification number: C07D401/04 ,  A61K31/4545 ,  A61K31/496 ,  C07D209/14 ,  C07D211/14 ,  C07D401/06 ,  C07D401/14 ,  C07D405/04 ,  C07D413/04

Abstract: There are provided compounds represented by the general formula (I): [wherein Ar is indole etc., R1 is hydrogen etc., B is bond, or B—N—R1 forms a ring structure and is piperidine etc., n is 0, 1, etc., A is trimethylene, butylene, etc., Q is piperidine, isoindoline, etc.], or pharmacologically acceptable acid addition salts thereof, and &agr;1B adrenoceptor antagonists composed of these substances. The invented compounds are antagonists having high affinity for &agr;1B adrenoceptor and are useful as pharmaceutical agents for use in prophylaxis/therapy of diseases (e.g., hypertension) in which &agr;1B adrenoceptor is involved or as pharmacological tools for elucidation of physiological activities mediated by &agr;1B adrenoceptor.

Abstract translation: 提供由通式（I）表示的化合物：[其中Ar为吲哚等，R 1为氢等，B为键或BNR 1形成环结构，为哌啶等，n 是0,1等，A是三亚甲基，亚丁基等，Q是哌啶，异吲哚啉等]或其药理学上可接受的酸加成盐，和由这些物质组成的α1B肾上腺素能受体拮抗剂。 本发明化合物是对α1B肾上腺素受体具有高亲和力的拮抗剂，并且可用作用于预防/治疗其中涉及α1B肾上腺素受体的疾病（例如高血压）的药物，或作为阐明由α1B肾上腺素受体介导的生理活性的药理学工具。

公开(公告)号：US20120258988A1

公开(公告)日：2012-10-11

申请号：US13509483

申请日：2010-11-12

Applicant: Takehiro Takahashi ,  Hiroki Kumagai ,  Takashi Kadowaki ,  Naoto Kubota ,  Tetsuya Kubota

Inventor： Takehiro Takahashi ,  Hiroki Kumagai ,  Takashi Kadowaki ,  Naoto Kubota ,  Tetsuya Kubota

IPC: A61K31/5585 ,  A61P3/10

CPC classification number: A61K31/343 ,  A61K31/4439 ,  A61K31/5575 ,  A61K2300/00

Abstract: A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.

Abstract translation: 用于糖尿病的治疗或预防剂包括作为PPAR-γ激动剂的噻唑烷衍生物作为有效成分，其表现出PPAR-γ激动剂的副作用降低。 用于糖尿病的治疗或预防剂包括特定的IP激动剂如贝前列素钠（BPS）和吡咯烷衍生物如吡格列酮或其药学上可接受的盐。 由于治疗或预防剂表现出足够有效的降血糖作用，而不伴随PPAR-γ激动剂特征的副作用，因此该药剂可用作糖尿病的高度安全有效的治疗或预防剂。

公开(公告)号：US06452539B2

公开(公告)日：2002-09-17

申请号：US09730424

申请日：2000-12-05

Applicant: Hironori Katou ,  Shuji Kawabata ,  Hiroki Kumagai

Inventor： Hironori Katou ,  Shuji Kawabata ,  Hiroki Kumagai

IPC: H04B7185

CPC classification number: H04B1/3838 ,  H01Q1/28 ,  H01Q3/00

Abstract: An electromagnetic wave radiation control apparatus includes an antenna, a modulator, an amplifier, and a radiation control unit. The modulator modulates a carrier wave based on a transmission signal to output a modulated signal, wherein the modulator stops the output of the modulated signal in response to a power off command. The amplifier amplifies the modulated signal such that the amplified signal is radiated as electromagnetic wave from the antenna, when the modulated signal is outputted from the modulator. The radiation control unit generates the power off command to the modulator, when radiation of electromagnetic wave in a current radiation direction of the antenna is inhibited, or when a level of a reception signal by the antenna is equal to or lower than a predetermined minimum level.

Abstract translation: 电磁波辐射控制装置包括天线，调制器，放大器和辐射控制单元。 调制器基于传输信号调制载波以输出调制信号，其中调制器响应于断电指令停止调制信号的输出。 当调制信号从调制器输出时，放大器放大调制信号，使得放大的信号作为电磁波从天线辐射。 当天线的当前辐射方向的电磁波的辐射被抑制时，或当天线的接收信号的电平等于或低于预定的最小电平时，辐射控制单元向调制器产生断电命令 。